JAZZJazz PharmaceuticalsSigning up patients
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Breast Cancer · Gastric Cancer · Esophageal Cancer · Gastroesophageal Cancer · Colorectal Cancer · Endometrial Cancer · Non-small Cell Lung Cancer · Ovarian Cancer · Urothelial Carcinoma · Salivary Gland Cancer · Pancreatic Cancer · HER-2 Protein Overexpression
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.5
3 insiders sold shares within a month
Since May 28, 2026 · was worth 10, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 200 (planned)
- Started
- Jan 14, 2025
- Main results expected
- Dec 31, 2026
- Fully finished
- Dec 31, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR
Measured over: Up to 2.5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.5, since 2026-05-28, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06695845 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC